2,861 Shares in Natera, Inc. $NTRA Purchased by Retireful LLC

Retireful LLC purchased a new position in Natera, Inc. (NASDAQ:NTRA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,861 shares of the medical research company’s stock, valued at approximately $658,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its position in shares of Natera by 4.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 22,448 shares of the medical research company’s stock worth $5,143,000 after acquiring an additional 923 shares during the last quarter. Guided Capital Wealth Management LLC increased its position in Natera by 24.3% during the fourth quarter. Guided Capital Wealth Management LLC now owns 15,786 shares of the medical research company’s stock worth $3,616,000 after purchasing an additional 3,085 shares during the last quarter. Saxony Capital Management LLC acquired a new position in Natera during the fourth quarter worth approximately $208,000. J. Safra Sarasin Holding AG purchased a new position in Natera during the fourth quarter worth approximately $2,825,000. Finally, Private Advisory Group LLC purchased a new position in Natera during the fourth quarter worth approximately $412,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Stock Up 1.6%

Natera stock opened at $203.21 on Thursday. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36. The firm has a fifty day moving average of $208.63 and a 200-day moving average of $208.92. The firm has a market capitalization of $28.80 billion, a P/E ratio of -132.82 and a beta of 1.68.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The business had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same quarter in the previous year, the business posted ($0.41) EPS. On average, research analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 23,205 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total transaction of $5,447,141.70. Following the transaction, the insider owned 144,992 shares in the company, valued at $34,035,422.08. The trade was a 13.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Michael Burkes Brophy sold 37,175 shares of the company’s stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $242.54, for a total value of $9,016,424.50. Following the completion of the sale, the chief financial officer directly owned 64,123 shares of the company’s stock, valued at $15,552,392.42. The trade was a 36.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 318,344 shares of company stock valued at $74,091,416. 5.63% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. TD Cowen reissued a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Citigroup initiated coverage on Natera in a research report on Wednesday, January 7th. They issued a “buy” rating and a $300.00 target price on the stock. BTIG Research lifted their target price on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a report on Friday, December 5th. Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Finally, Morgan Stanley cut their price objective on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.47.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.